Amicus Therapeutics (FOLD) : Cqs Cayman Lp added new position in Amicus Therapeutics during the most recent quarter end. The investment management firm now holds 1,390,000 shares of Amicus Therapeutics which is valued at $9,646,600 , the company said in a statement filed on Aug 9, 2016 with the SEC.Amicus Therapeutics makes up approximately 2.23% of Cqs Cayman Lp’s portfolio.
Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in FOLD in the latest quarter, The investment management firm added 2,128 additional shares and now holds a total of 15,808 shares of Amicus Therapeutics which is valued at $109,708.Convector Capital Management Lp reduced its stake in FOLD by selling 28,400 shares or 12.12% in the most recent quarter. The Hedge Fund company now holds 206,000 shares of FOLD which is valued at $1,442,000. Amicus Therapeutics makes up approx 1.89% of Convector Capital Management Lp’s portfolio.Achievement Holdings reduced its stake in FOLD by selling 10,000 shares or 20.0% in the most recent quarter. The Hedge Fund company now holds 40,000 shares of FOLD which is valued at $285,200. Amicus Therapeutics makes up approx 0.04% of Achievement Holdings’s portfolio.Candriam Luxembourg S.c.a. boosted its stake in FOLD in the latest quarter, The investment management firm added 90,000 additional shares and now holds a total of 709,900 shares of Amicus Therapeutics which is valued at $5,061,587. Amicus Therapeutics makes up approx 0.13% of Candriam Luxembourg S.c.a.’s portfolio.Cutler Group Lp reduced its stake in FOLD by selling 284 shares or 3.93% in the most recent quarter. The Hedge Fund company now holds 6,934 shares of FOLD which is valued at $40,148.
Amicus Therapeutics closed down -0.13 points or -1.86% at $6.87 with 12,26,950 shares getting traded on Wednesday. Post opening the session at $6.99, the shares hit an intraday low of $6.79 and an intraday high of $7.13 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Amicus Therapeutics reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36.Analysts expectations of $ .17.
Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.